Kang, H., Lim, A., Clark, A., Colón González, F. J., Clapham, H. E., Carrera, J.-P., Kim, J.-H., Auzenbergs, M., Lakshminarayanan, P., López-Vergès, S., Sim, S. Y., Han, S. M., Cerqueira-Silva, T., Endy, T., Cucunubá, Z. M., Edmunds, W. J., Sahastrabuddhe, S., Brady, O. J., & Abbas, K. (2025).
Age-specific chikungunya outbreak response immunisation strategies in Brazil: a modelling study. eClinicalMedicine, 90, 103690.
https://doi.org/10.1016/j.eclinm.2025.103690
Summary
Background
Two chikungunya vaccines, Ixchiq and Vimkunya are licensed. In April 2025, Brazil is the first endemic country to license Ixchiq, but optimal age groups for vaccination remain unclear. Our aim is to model the public health impact of age-specific chikungunya outbreak response immunisation strategies in Brazil and infer broader implications for vaccine use case scenarios in outbreak prone regions.
